Pralatrexate

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Retrieved on: 
星期四, 三月 28, 2024
Agreement, Transplant, CASI Pharmaceuticals, CASI, Patient, Travel, PTCL, Immunoglobulin G, CMC, Depreciation, Bone marrow, Therapy, VCP, Marketing, Research, Cleave, Pralatrexate, MCL, Rituximab, AML, Pembrolizumab, Trial of the century, Myelodysplastic syndrome, Melphalan, MDS, Clinical trial, Follicular lymphoma, Republic, Multiple myeloma, Acute myeloid leukemia, Annual report, National Medical Products Administration, Haematopoietic system, FDA, Cayman, CD19, NMPA, COVID-19, CTA, HKIAC, NHL, Non-Hodgkin lymphoma, MICL, Pharmaceutical industry

BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.

Key Points: 
  • BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
  • CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA®, 33% lower than the same period in 2022.
  • 2023 marks a major milestone for CASI and our partner Juventas; Inaticabtagene Autoleucel (CNCT-19 CAR-T cell therapy) was approved by National Medical Products Administration (NMPA) in November 2023.
  • As of December 31, 2023, CASI had cash, cash equivalents and short term investment of $29.1 million compared to $48.6 million as of December 31, 2022.

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

Retrieved on: 
星期六, 十二月 9, 2023
Patient, Peripheral, Eligibility, Survival, Clinical trial, Lymphoma, Overalls, OS, Data, PFS, Pralatrexate, Immunocompetence, Pharmaceutical industry

BURLINGAME, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from its Phase 1/1b clinical trial of soquelitinib in patients with relapsed PTCL. Soquelitinib demonstrated durable anti-tumor activity, evidenced by progression free survival, duration of response and overall survival rates that exceed current standard of care therapies for patients with relapsed PTCL. The data continues to support the advancement of soquelitinib into a Phase 3 registrational clinical trial in PTCL.

Key Points: 
  • The data continues to support the advancement of soquelitinib into a Phase 3 registrational clinical trial in PTCL.
  • Figure 1: Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma.
  • Figure 3: Table Comparing Soquelitinib Data from Phase 1 (Eligible and Ineligible) to Data Reported for Pralatrexate and Belinostat.
  • Soquelitinib data are shown for both the eligible and ineligible patient populations from the Phase 1/1b trial reported above.

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

Retrieved on: 
星期二, 八月 1, 2023
Agreement, PTCL, US Foods, Therapy, Doctor of Philosophy, Assignment, CASI, MICL, Medicine, CASI Pharmaceuticals, Republic, Patient, National Medical Products Administration, FDA, Pralatrexate, Good, Food, NMPA, Generic drug, Pharmaceutical industry

FOLOTYN® (Pralatrexate) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ("PTCL").

Key Points: 
  • FOLOTYN® (Pralatrexate) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma ("PTCL").
  • This product was approved by both the US Food and Drug Administration ("FDA") and China's National Medical Products Administration (NMPA) for PTCL.
  • Under the terms of the Agreement, CASI will assume MICL's rights and obligations with respect to the commercialization of FOLOTYN® in China.
  • We look forward to this exciting launch and bringing this novel medicine to PTCL patients in China," said Dr. Ashish Anvekar, President of Acrotech Biopharma.

Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Retrieved on: 
星期四, 十二月 8, 2022
Health, Science, Pharmaceutical, Research, Oncology, Thrombocytopenia, Pralatrexate, Dialysis, Kidney, Fresenius (company), Patient, Toxicity, Liver function tests, Probenecid, Nausea, Mucositis, Fatigue, FDA, Risk, Birth, Multimedia, Tumor lysis syndrome, Fetus, ANC, Platelet, Pharmaceutical industry, Medical imaging, Birth control, Health, Science, Pharmaceutical, Research, Oncology

Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn, for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Key Points: 
  • Fresenius Kabi announced today it has introduced Pralatrexate Injection, a generic equivalent to Folotyn, for the treatment of relapsed or refractory peripheral T-cell lymphoma.
  • (Photo: Business Wire)
    Fresenius Kabi is committed to expanding access to high-quality, high-value oncology medicines, said John Ducker, president and CEO of Fresenius Kabi USA.
  • Fresenius Kabi Pralatrexate Injection provides clinicians and patients with a generic treatment option for adult patients with relapsed or refractory peripheral T-cell lymphoma.
  • Fresenius Kabi Pralatrexate Injection is available in two single-dose vial presentations: 20 mg/1 mL and 40 mg/2 mL.